Zai Lab Announces Breakthrough Therapy Designation Granted for Bemarituzumab (FPA144) in China
Potential first-in-class therapy for a subset of gastric and gastroesophageal (GEJ) cancers that overexpress fibroblast growth factor receptor 2 (FGFR2b)...








